|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.33 USD | +2.27% |
|
+0.28% | +18.88% |
| 08-06 | Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating | MT |
| 08-05 | Arcus Biosciences, Inc., Q2 2026 Earnings Call, Aug 05, 2026 |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,563 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 20.85% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 3,102 | 3,381 | 3,236 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 50.13% | 8.99% | -4.3% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -8.27x | -7.85x | -9.76x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 18.8x | -17.3x | 18.6x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -1.98x | -1.49x | 0.5x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 41.7x | 38.2x | 17.6x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 36.3x | 36.2x | 16x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -6.81x | -6.82x | -11x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -6.67x | -6.94x | -7.43x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -12x | -10.1x | -17x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -8.33% | -9.86% | -5.88% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.427 | -3.608 | -2.903 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 85.52 | 93.29 | 202.2 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -455.4 | -496.1 | -293.6 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -464.9 | -487.5 | -435.8 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -437.7 | -443.1 | -377.3 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -460.8 | -182 | -327.3 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 28.33 | 28.33 | 28.33 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 125,773 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 21/02/24 | 25/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.27x | 36.27x | -6.81x | -.--% | 3.56B | |
| 33.27x | 5.94x | 17.68x | 0.96% | 48.7B | |
| -22.15x | 304.02x | -19.9x | -.--% | 42.05B | |
| 29.93x | 2.99x | 12.91x | -.--% | 38.26B | |
| 43.85x | 4.94x | 27.58x | -.--% | 37.5B | |
| 29.67x | 8.57x | 21.53x | 0.39% | 31.44B | |
| 33.27x | 5.44x | 24.74x | -.--% | 16.33B | |
| 23.25x | 2.04x | 8.83x | 1.16% | 13.98B | |
| 53.86x | 3.78x | 14.82x | -.--% | 12.68B | |
| Average | 24.08x | 41.56x | 11.26x | 0.28% | 27.17B | |
| Weighted average by Cap. | 24.27x | 57.01x | 11.94x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
